The following four abstracts were selected as the best scientific submissions to the ASBMT meeting held in Miami, FL in Spring 1998  by Johnson, B. et al.
Biology of Blood and Mar row Tran splantation 4:1-2 (1998)
© 1998 Am ' S ' .errcan oClety for Blood and Marrow Tra nsplantat ion
The following four abstracts were selected as the best
scientific submissions to the ASBMT meeting held in
Miami, FL in Spring 1998
Donor-derived Thy I+ cells suppress GVHD afte r DLI
B. ] o/JIIso//, Eo BI'c/.:I'I; R. Truitt
A!rtl im/ CoII"!l,/' 0f IVis(oIlI i ll, Mihoaukre, IV/
Delayed infusion(s) of donor T ce lls following allogene ic Bi\·rr (often referred to as DLI) have been give n for th e success fu l
tr eatment o f posnran spl ant leukemia rel ap se. For unknown reasons th e incid en ce and sevcrirv o f GVI-I D foll owing D LI are
less th an expec ted cons ide ring th e rclari velv lar ge number s o f T ce lls admin ist ered . Pre\ 'iou s' stud ies in ou r lahoraro rv usin g
l~lll~ln e mod els of MH C -compatihle and hapl o-mismarch cd (parent into 1'1) allogen eic BMT demonstrat ed that GVH D
fOU d he co mpletely avoided if administration of donor T ce lls was dela yed until at least _~ weeks po srtran sp lnnr . Recently, we
2~~Te used,a full l\~HC-,mism,~tched model (C57 BL/o into AKR) to det ermine hem: incr eased in~munogenetic dispari ty a tTe~ts
IIIG\ L reactions fo llowing DLI . In co ntrast to th e MI-IC -match ed model , ('VI-ID was st ill o bserved wh en i\·lH C -llll S-
mat ch ed donor T cel ls were infused 3 weeks posrrransplanr. Limiting dilution ana lvscs wer e co nduc te d to det e rmine th e fre-
(]lIen cy of allo reactive CT L and IL-2-sccretin ~ T helper ce lls in th~ splee ns o f micc 7 da ys aft er DLI treatmen t. The pr es-
enc~ ,of G V1-1D in the ivl I-1 C -m ismatchcd mod~ 1 co rre late d with persist en ce o f T helper fl;n ction . Delayed in fusion o f e ither
P~":lhed C D4 + or C DR+ 'I' ce lls ., weeks posrrranspl unt resulted in signifcant ly less G V I-I D. No C V I-I-associate d mortality
W,IS ohse rved tilllowing DLI with purifi ed donor C D4 ' T ce lls. If th e infusion of un sep amted donor T ce lls was delayed on e
more week (4 weeks posrtrausplanr), clin icallv evide nt GVI-I was co m pletely ab sent. Sin ce non -T ce ll-de p leted don or Hlv!
~::~~I~l sed , in th ese studies, expe rime nts were (ies igned to assess wh ether 13M -d eri ved donor T ce lls (T hyl.Z+) co ntr ibute d to
d~ 1 .1I? f o ll o~~i~l g D L1. AKR recipiel~ts wer e given non-T-depl c~e~1 C57 BL:o 13M (day .O), tr eated .o r not tJ~e:lted ~I.~:iv(} with
1.letll1g ant i I hyl.Z monoclonal unribodv (days 10-12 po sr-Hvl I ), th en given DLI With conjrc ruc Bo.PLI hvl.l I ce lls at
;:a;;l ou ~ tim es posrtrunspl anr. C om pared ~vith ;mtreat ed mice, th e .m ri-T hy l.Ze-rrcared mice d~veloped mo re ~e \'e re G VI ID
t~ II~ \~mg DLI a~ indicat ed hy incre~sed morta.li~' a ~ l d bo.dy weight ,loss: Thes~ results sugges t th at ~ I on or-derivcd Thy!.2 +
, In th e 13M inocu lum suppress (,V 1-1 rcacnvity fol lowing D L1. Studies are In pro gr ess to det ermine wh ether these sup-
pressor ce lls ar c T ce lls or non-T ce lls that express Thyl,
~ouble class II micromismatches increase th e risk of acute graft- vs.- hos t disease afte r unrelat ed donor marrow
ransplantation with t acrolimus and minimethotrexate for prophylax is
;(,i Jlr~l'pi(} r/.:{/ , C:. lppulit), I. Khouri, K: C/t'IIr)', 1/. Fischer; II. Fn:/J~'bl', 0: I.l'nb~'J 'Z" N. Urno, R, i\!1'!Jm . S. Gil'll /I,]. G'!il'1l'.l'/.:i,
\ . DO/JI/IO, D. (/".\'tOIl, I. n nIllIlJd l7l" 'I ff;, B. Andersson, I ~ Anderlini, R. ( bil/llp/III
. 1.1) '111/" " c U ' , /',,/ . // rx
" { t I JOII ~lI l1ff '" 41'1II l' l; IlI z 't'n'/~Y (~ CXII .\", «aston. ~
Rand oll1i zed studies have dem on strated that rucr olimus is more effec tive th an is cyc los po rinc for pr evention o f e V I-11) after
,\-1 f) BMT \Ve review ed o ur expe rience usin g tucrolimus for M U I) BMT to d ~tennine th e effec t of m icromism at ch es on
OUtco l1le. Eighty ad ults o f medi an age .'4 years with hemat ol ogic malign an cies received a myelonhlari ve regim en and an
~;1(1l1 ;.1I.1ipulated m:llT()\~' transplant . from an unrel at ed dotlO~' .se ro l.ogically mat ch ed flU', II LA-,~ , I II::\- B" and I I ~ "A-D RB I.
,llt:clrlar class II rypu u; was performed hy seque nce -s pec ific pl'lln er polym era se cham reacti on . Fift y-four pati ent -d on or
pa.lrs we re mo lecul urlv match ed for 1-1 LA- D RBI and II LA-I)() 13 I , 14 had a mol ecul ar mism atch at e ithe r locus, and 12 had a
1l:lcroll1ism atch at 11I ;th loc i. ' Iacro lim us was admini ster ed at o.m mg/k g/day i.v, C I. and doses were adj uste d to maintain
" ho le blood II\ l x levels of 5- 15 mg/mL. MTX 5 mg/m ~ was given o n duvs I, _" 6, and II . Pati ents with eVllD th at per sist -
eld despit e high -d ose ste ro ids for > 4Hhours were co ns ide red refractory. the ac tuar ial risk o f grade 11 -1 V eV111) was 42% in
t Ie l!lat ch ed g ro up, 46% with one mismur ch , and 7 1% wit h two mism atch es. ( ;rade 111 - 1V ( ;V I ID occurred in 16, 27 , and
60 %, resp ect ively. Refra ctory e VI ID occurred in 20, 23, and 60 '){, of pat ients, respecti ve ly. Only th e pati ents with m is-
I~la tches in hoth II LA- D RBI and I-ILA-DQBI had a significant incr ease in eVI II) . ' Ihc ro lim us and mini .vllX is not cffec-
tlve C;VI-I () prophylaxis with a douhlc class II mol ecul ar mism at ch .
Expanded CD3+NKI.1 + cells demonstrate an In vivo graft-vs.-Iymphoma effect without acute GVHD
M. Ito,J. Baker,JA. Sbizuru, R.S. Negrin
Stanford University Medical Center, Stanford, CA
Although transplantation of highly purified allogeneic hematopoietic stem cells (HSCs) may prove beneficial in the reduction
of'graft-vs.-host disease (GVHD), the potential loss of a graft-vs.-leukemiallymphoma (GVL) effect may offset this advan-
tage. An ideal approach would be to transplant pure HSCs and selected populations of cells that confer GVL witbout
GVHD. We have carried out transplants of purified allogeneic HSCs in mice inoculated with the B cell lymphoma, BCLl,
and demonstrated that allogeneic HSC transplants alone have no GVL effect. To augment GVL, in vitro expanded spleno-
cytes, which have potent in vitro anti-tumor cell activity, have been added. The expanded cells are generated by long-term (3
weeks) culture of splenoeytes in the presence of IFN-"f, IL-2, and adherent a-CD3 monoclonal antibodies (mAbs). The
expanded cells are of one fredominant phenotype (>90%), as determined by fluorescence-activated cell sorter (FACS) analy-
sis, namely CD3+, NKl.1 ,CDS+, and a/13 T cell receptor positive. The calculated fold expansion of cells of this phenotype
is > 100. We have studied the tumor suppressive activity of unprimed expanded CD3 +NK1.1 + cells derived from mouse
spleen in an in vivo lymphoma relapse model. To establish a model of tumor relapse Balb/c (H~2a) mice were inoculated with
103 BCLl tumor cells. One week later they received lethal irradiation and 6000 purified HSCs of the phenotype Thy-
11oLin-lloSca_l+ with or without donor matched expanded CD3+NKl.l+ cells. Purified Thy-11oLin-lIoSca-l+ HSCs effec-
tively reconstitute hematopoiesis in irradiated mice, but have no GVL activity. The donor cells were from MHC-mis-
matcbed C57BLIKa (lI-2b) mice. Relapse was monitored by the appearance of splenomegaly and FACS analysis of peripher-
al blood staining with a BCL1 specific mAb, 6A5. All mice were documented to be hematopoietic cell chimeras by FACS
analysis, and were without evidence of acute GVlID. Control mice that received bone marrow + 106 unfractionated spleen
cells all died of GV1ID within 7 days. All control mice (n=15) transplanted with C57BLIKa HSC only died of the tumor
within 6 weeks following lISC transplant. In contrast, 80% of mice transplanted with 103 BCLl cells + C57BLIKa lISC +
107 expanded CD3 +NK1.1 + cells are alive and well 10 weeks posttransplant. We conclude that CD3 +NK1.1 + cells are capa-
ble of augmenting GVL following allogeneic lISC transplants without causing signifcant GVHD.
Kinetics and symmetry of Initial cell division of human CD34+/cD38- cells from different ontogenic age
S. Huang, K. Francis, P. Law, R. Ramakrishna, so. Palsson, A.D. Ho
University ofCalifornia, San Diego, LaJolla, CA
To monitor the replication of hematopoietic progenitor cells (HPC), we have developed a time-lapse camera system to
observe directly cell divisors. In this study, we combined the system with index sorting and single-cell culture, and correlated
the early replication behavior of CD34+/CD38+ cells to the ontogenic age of tissues, such as fetal liver (FV), cord blood
(CB), and adult marrow (AM). Cell divisions were monitored every 12 hours for 8 days in medium containing SCF, IL-3, IL-
6, GM-CSF, and Epo. Replication of each HPC was measured using membrane dye PKH-26. Symmetry of the intital cell
division and the division kinetics of progeny cells were calculated from the singly sorted CD34+/CD38+ cells.
Division/total Cloning Asvmetric division! Asymmetric division!
N cell (%) efficiency (%) total cell (%) total division (%)
FV 8 80,4 ± 10.2 56.6 ± 19.3 37.6 ± 14.8 48.1 ± 20
cn 4 76.3 ± 3.8 30.9 ± 7.4 34.7 ± 14.7 45.6 ± 17.5
AM 5 47.1 ± 15.6 17.4±8.7 20.6 ± 10.4 44.7 ± 19.7
Our results also showed that 36-48 hours were required for CD34+ /CD38+ cells to complete the first mitosis, but only 12
hours for each subsequent division. The kinetic course was independent of ontogenic age. We conclude that: (1) -40% of
intital cell divsions were definitely asymmetric in which one of the daughter cells became quiescent, while the other prolifer-
ated exponentially; (2) the percentage of cells undergoing asymmetric divisions decreases with ontogenic age, FV>CB>AMj
(3) the ratio of asymmetric to symmetric divisions is not correlated with ontogenic age. This unique technology will permit
precise definition ofeytokine and cellular determinants in the replication of primitive lIPC.
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